The effect of energy and protein intakes on boar libido, semen characteristics, and plasma... - Abstract - Europe PMC
Europe PMC requires Javascript to function effectively.
Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.
Search worldwide, life-sciences literature
(PMID:7982834)
Department of Animal Science, University of Nebraska, Lincoln .
Journal Article
)- subscription required
Show all items
Show all items
Show all items
Show all items
Show all items
Show all items
Show all items
Show all items
Show all items
Show all items
Show all items
Show all items
Show all items
Show all items
Show all items
Show all itemsJournal of Education and Psychology, Vol. 29
No. 2
, Pages 339
-368
Journal of Education and Psychology
No. 2
, Pages 339
The Relationships between Pupils’ Explanatory Style, Domain Knowledge, Creative Life Experience and Their Technological Creativity (Article written in Chinese)
Fang-Yi CHENG & Yu-Chu YEH
Recent research on creativity has put great emphasis on how multiple systems influence an individual’s creativity development. The main purposes of this study were (a) to understand the current situation of pupils’ explanatory style, domain knowledge, creative life experience, and tech and (b) to explore the relationships between pupils’ grade, explanatory style, domain knowledge, creative life experience and their technological creativity. The participants included 418 pupils. The employed instruments were The Questionnaire of Children’s Explanatory Style, The Questionnaire of Creative Life Experience, The Test of Technological Creativity, and the scores of Science.
The main findings in this study were as follows: (a) There were grade differences on the pupils’ (b) although no significant interaction effect of grade × explanatory style on technological creativity was found, there were significant m (c) domain knowledge contributed to the pupils’ performance on tech (d) creative life experience had significant effects on the pupils’ technological creativity, and the indices of “language” and “performing arts” had the highest correlation with tech and (e) grade, explanatory style, domain knowledge, and creative life experience could effectively predict the pupils’ ability group membership of technological creativity, and grade as well as domain knowledge had better predictive power.
crea technological creativity
Mail any comments and suggestions toMEDLINE - Resultado página 1
Base de dados :
Pesquisa :
C04.588.614.250.195 [Categoria DeCS]
Referências encontradas :
Mostrando:
no formato [Longo]
página 1 de 8703
ir para página &&&&&&&&&&&&&&&&&&&&&&&&
para imprimir
Fotocópia
Autor:Sun L; Joh DY; Al-Zaki A; Stangl M; Murty S; Davis JJ; Baumann BC; Alonso-Basanta M; Kaol GD; Tsourkas A; Dorsey JFTítulo:Theranostic Application of Mixed Gold and Superparamagnetic Iron Oxide Nanoparticle Micelles in Glioblastoma Multiforme.
Fonte:J Biomed N 12(2):347-56, 2016 Feb.
ISSN:País de publica??o:United States
Idioma:engResumo:The treatment of glioblastoma multiforme, the most prevalent and lethal form of brain cancer in humans, has been limited in part by poor delivery of drugs through the blood-brain barrier and by unclear delineation of the extent of infiltrating tumor margins. Nanoparticles, which selectively accumulate in tumor tissue due to their leaky vasculature and the enhanced permeability and retention effect, have shown promise as both therapeutic and diagnostic agents for brain tumors. In particular, superparamagnetic iron oxide nanoparticles (SPIONs) have been leveraged as T2-weighted MRI contrast agents for tumor d and gold nanoparticles (AuNP) have been demonstrated as radiosensitizers capable of propagating electron and free radical-induced radiation damage to tumor cells. In this study, we investigated the potential applications of novel gold and SPION-loaded micelles (GSMs) coated by polyethylene glycol-polycaprolactone (PEG-PCL) polymer. By quantifying gh2ax DNA damage foci in glioblastoma cell lines, we tested the radiosensitizing efficacy of these GSMs, and found that GSM administration in conjunction with radiation therapy (RT) led to ~2-fold increase in density of double-stranded DNA breaks. For imaging, we used GSMs as a contrast agent for both computed tomography (CT) and magnetic resonance imaging (MRI) studies of stereotactically implanted GBM tumors in a mouse model, and found that MRI but not CT was sufficiently sensitive to detect and delineate tumor borders after administration and accumulation of GSMs. These results suggest that with further development and testing, GSMs may potentially be integrated into both imaging and treatment of brain tumors, serving a theranostic purpose as both an MRI-based contrast agent and a radiosensitizer.
Tipo de publica??o: JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
Nome de subst?ncia:0 (Contrast Media); 0 (Magnetite Nanoparticles); 0 (Micelles);
(Gold); G6N3J05W84 (ferumoxides); K3R6ZDH4DU (Dextrans)
para imprimir
Fotocópia
Texto completo
Autor:Chen Q; Boire A; Jin X; Valiente M; Er EE; Lopez-Soto A; Jacob LS; Patwa R; Shah H; Xu K; Cross JR; Massagué JEndere?o:Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA....
Título:Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer.
Fonte:N 533(, 2016 May 26.
ISSN:País de publica??o:England
Idioma:engResumo:Brain metastasis represents a substantial source of morbidity and mortality in various cancers, and is characterized by high resistance to chemotherapy. Here we define the role of the most abundant cell type in the brain, the astrocyte, in promoting brain metastasis. We show that human and mouse breast and lung cancer cells express protocadherin 7 (PCDH7), which promotes the assembly of carcinoma-astrocyte gap junctions composed of connexin 43 (Cx43). Once engaged with the astrocyte gap-junctional network, brain metastatic cancer cells use these channels to transfer the second messenger cGAMP to astrocytes, activating the STING pathway and production of inflammatory cytokines such as interferon-α (IFNα) and tumour necrosis factor (TNF). As paracrine signals, these factors activate the STAT1 and NF-κB pathways in brain metastatic cells, thereby supporting tumour growth and chemoresistance. The orally bioavailable modulators of gap junctions meclofenamate and tonabersat break this paracrine loop, and we provide proof-of-principle that these drugs could be used to treat established brain metastasis.
Tipo de publica??o: JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.
Nome de subst?ncia:0 (Benzamides); 0 (Benzopyrans); 0 (Cadherins); 0 (Connexin 43); 0 (Interferon-alpha); 0 (MPYS protein, human); 0 (MPYS protein, mouse); 0 (Membrane Proteins); 0 (NF-kappa B); 0 (Nucleotides, Cyclic); 0 (PCDH7 protein, human); 0 (PCDH7 protein, mouse); 0 (STAT1 Transcription Factor); 0 (Tumor Necrosis Factors); 0 (cyclic guanosine monophosphate-adenosine monophosphate); 2XD9773ZMN (tonabersat); 48I5LU4ZWD (Meclofenamic Acid)
para imprimir
Fotocópia
Texto completo
Autor:Jordan JT; Gerstner ER; Batchelor TT; Cahill DP; Plotkin SREndere?o:Pappas Center for Neuro-Oncology, Massachusetts General Hospital, Boston, Massachusetts....
Título:Glioblastoma care in the elderly.
Fonte:C 122(2):189-97, 2016 Jan 15.
ISSN:País de publica??o:United States
Idioma:engResumo:Glioblastoma is common among elderly patients, a group in which comorbidities and a poor prognosis raise important considerations when designing neuro-oncologic care. Although the standard of care for nonelderly patients with glioblastoma includes maximal safe surgical resection followed by radiotherapy with concurrent and adjuvant temozolomide, the safety and efficacy of these modalities in elderly patients are less certain given the population's underrepresentation in many clinical trials. The authors reviewed the clinical trial literature for reports on the treatment of elderly patients with glioblastoma to provide evidence-based guidance for practitioners. In elderly patients with glioblastoma, there is a survival advantage for those who undergo maximal safe resection, which likely includes an incremental benefit with increasing completeness of resection. Radiotherapy extends survival in selected patients, and hypofractionation appears to be more tolerable than standard fractionation. In addition, temozolomide chemotherapy is safe and extends the survival of patients with tumors that harbor O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation. The combination of standard radiation with concurrent and adjuvant temozolomide has not been studied in this population. Although many questions remain unanswered regarding the treatment of glioblastoma in elderly patients, the available evidence provides a framework on which providers may base individual treatment decisions. The importance of tumor biomarkers is increasingly apparent in elderly patients, for whom the therapeutic efficacy of any treatment must be weighed against its potential toxicity. MGMT promoter methylation status has specifically demonstrated utility in predicting the efficacy of temozolomide and should be considered in treatment decisions when possible. Cancer -197. (C) 2015 American Cancer Society.
Tipo de publica??o: COMPARATIVE STUDY; JOURNAL ARTICLE; REVIEW
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
Autor:Emir UE; Larkin SJ; de Pennington N; Voets N; Plaha P; Stacey R; Al-Qahtani K; Mccullagh J; Schofield CJ; Clare S; Jezzard P; Cadoux-Hudson T; Ansorge OEndere?o:The FMRIB Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom. uzay.emir@ndcn.ox.ac.uk....
Título:Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations.
Fonte:Cancer R 76(1):43-9, 2016 Jan 1.
ISSN:País de publica??o:United States
Idioma:engResumo:Mutations in the isocitrate dehydrogenase genes (IDH1/2) occur often in diffuse gliomas, where they are associated with abnormal accumulation of the oncometabolite 2-hydroxyglutarate (2-HG). Monitoring 2-HG levels could provide prognostic information in this disease, but detection strategies that are noninvasive and sufficiently quantitative have yet to be developed. In this study, we address this need by presenting a proton magnetic resonance spectroscopy ((1)H-MRS) acquisition scheme that uses an ultrahigh magnetic field (≥ 7T) capable of noninvasively detecting 2-HG with quantitative measurements sufficient to differentiate mutant cytosolic IDH1 and mitochondrial IDH2 in human brain tumors. Untargeted metabolomics analysis of in vivo (1)H-MRS spectra discriminated between IDH-mutant tumors and healthy tissue, and separated IDH1 from IDH2 mutations. High-quality spectra enabled the quantification of neurochemical profiles consisting of at least eight metabolites, including 2-HG, glutamate, lactate, and glutathione in both tumor and healthy tissue voxels. Notably, IDH2 mutation produced more 2-HG than IDH1 mutation, consistent with previous findings in cell culture. By offering enhanced sensitivity and specificity, this scheme can quantitatively detect 2-HG and associated metabolites that may accumulate during tumor progression, with implications to better monitor patient responses to therapy.
Tipo de publica??o: JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
Nome de subst?ncia:0 (Glutarates);
(alpha-hydroxyglutarate); EC 1.1.1.41 (Isocitrate Dehydrogenase); EC 1.1.1.41 (isocitrate dehydrogenase 2, human); EC 1.1.1.42. (IDH1 protein, human)
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
Autor:Yang Y; Hernandez R; Rao J; Yin L; Qu Y; Wu J; England CG; Graves SA; Lewis CM; Wang P; Meyerand ME; Nickles RJ; Bian XW; Cai WEndere?o:Department of Radiology, University of Wisconsin-Madison, Madison, WI 53705; Department of Pathology, Southwest Hospital, Third Military Medical University, Chongqing, China 400038;...
Título:Targeting CD146 with a 64Cu-labeled antibody enables in vivo immunoPET imaging of high-grade gliomas.
Fonte:Proc Natl Acad Sci U S A; 112(47):E15 Nov 24.
ISSN:País de publica??o:United States
Idioma:engResumo:Given the highly heterogeneous character of brain malignancies and the associated implication for its proper diagnosis and treatment, finding biomarkers that better characterize this disease from a molecular standpoint is imperative. In this study, we evaluated CD146 as a potential molecular target for diagnosis and targeted therapy of glioblastoma multiforme (GBM), the most common and lethal brain malignancy. YY146, an anti-CD146 monoclonal antibody, was generated and radiolabeled for noninvasive positron-emission tomography (PET) imaging of orthotopic GBM models. (64)Cu-labeled YY146 preferentially accumulated in the tumors of mice bearing U87MG xenografts, which allowed the acquisition of high-contrast PET images of small tumor nodules (?? 1/4
2 mm). Additionally, we found that tumor uptake correlated with the levels of CD146 expression in a highly specific manner. We also explored the potential therapeutic effects of YY146 on the cancer stem cell (CSC) and epithelial-to-mesenchymal (EMT) properties of U87MG cells, demonstrating that YY146 can mitigate those aggressive phenotypes. Using YY146 as the primary antibody, we performed histological studies of World Health Organization (WHO) grades I through IV primary gliomas. The positive correlation found between CD146-positive staining and high tumor grade (χ(2) = 9.028; P = 0.029) concurred with the GBM data available in The Cancer Genome Atlas (TCGA) and validated the clinical value of YY146. In addition, we demonstrate that YY146 can be used to detect CD146 in various cancer cell lines and human resected tumor tissues of multiple other tumor types (gastric, ovarian, liver, and lung), indicating a broad applicability of YY146 in solid tumors.
Tipo de publica??o: JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.
Nome de subst?ncia:0 (Antibodies, Monoclonal); 0 (Antigens, CD146); 0 (Copper Radioisotopes)
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
Autor:Luo H; Hernandez R; Hong H; Graves SA; Yang Y; England CG; Theuer CP; Nickles RJ; Cai WEndere?o:Department of Radiology, University of Wisconsin-Madison, Madison, WI 53705;...
Título:Noninvasive brain cancer imaging with a bispecific antibody fragment, generated via click chemistry.
Fonte:Proc Natl Acad Sci U S A; 112(41):15 Oct 13.
ISSN:País de publica??o:United States
Idioma:engResumo:Early diagnosis remains a task of upmost importance for reducing cancer morbidity and mortality. Successful development of highly specific companion diagnostics targeting aberrant molecular pathways of cancer is needed for sensitive detection, accurate diagnosis, and opportune therapeutic intervention. Herein, we generated a bispecific immunoconjugate [denoted as Bs-F(ab)2] by linking two antibody Fab fragments, an anti-epidermal growth factor receptor (EGFR) Fab and an anti-CD105 Fab, via bioorthogonal "click" ligation of trans-cyclooctene and tetrazine. PET imaging of mice bearing U87MG (EGFR/CD105(+/+)) tumors with (64)Cu-labeled Bs-F(ab)2 revealed a significantly enhanced tumor uptake [42.9 ± 9.5 percentage injected dose per gram (%ID/g); n = 4] and tumor-to-background ratio (tumor/muscle ratio of 120.2 ± 44.4 at 36 n = 4) compared with each monospecific Fab tracer. Thus, we demonstrated that dual targeting of EGFR and CD105 provides a synergistic improvement on both affinity and specificity of (64)Cu-NOTA-Bs-F(ab)2. (64)Cu-NOTA-Bs-F(ab)2 was able to visualize small U87MG tumor nodules (<5 mm in diameter), owing to high tumor uptake (31.4 ± 10.8%ID/g at 36 h postinjection) and a tumor/muscle ratio of 76.4 ± 52.3, which provided excellent sensitivity for early detection. Finally, we successfully confirmed the feasibility of a ZW800-1-labeled Bs-F(ab)2 for near-infrared fluorescence imaging and image-guided surgical resection of U87MG tumors. More importantly, our rationale can be used in the construction of other disease-targeting bispecific antibody fragments for early detection and diagnosis of small malignant lesions.
Tipo de publica??o: JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.
Nome de subst?ncia:0 (Antibodies, Bispecific); 0 (Antibodies, Neoplasm); 0 (Contrast Media); 0 (Immunoglobulin Fab Fragments)
para imprimir
Fotocópia
Texto completo
Autor:Gerstner ER; Ye X; Duda DG; Levine MA; Mikkelsen T; Kaley TJ; Olson JJ; Nabors BL; Ahluwalia MS; Wen PY; Jain RK; Batchelor TT; Grossman SEndere?o:Massachusetts General Hospital Cancer Center, Boston, Massachusetts (E.R.G., D.G.D., R.K.J., T.T.B.); Johns Hopkins Medical Center, Baltimore, Maryland (X.Y., S.G.); Martinos Center for Biomedical Imaging, Charlestown, Massachusetts (E.R.G., M.A.L.); Henry Ford Hospital, Detroit, Michigan (T.M.); Me...
Título:A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.
Fonte:Neuro O 17(10):15 Oct.
ISSN:País de publica??o:England
Idioma:engResumo:BACKGROUND: Despite being a highly vascularized tumor, glioblastoma response to anti-vascular endothelial growth factor (VEGF) therapy is transient, possibly because of tumor co-option of preexisting blood vessels and infiltration into surrounding brain. Integrins, which are upregulated after VEGF inhibition, may play a critical role in this resistance mechanism. We designed a study of cediranib, a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor, combined with cilengitide, an integrin inhibitor. METHODS: This phase I study was conducted through the Adult Brain Tumor Consortium in patients with recurrent glioblastoma. Once the maximum tolerated dose was determined, 40 patients enrolled in a dose expansion cohort with 20 being exposed to anti-VEGF therapy and 20 being naive. The primary endpoint was safety. Secondary endpoints included overall survival, proportion of participants alive and progression free at 6 months, radiographic response, and exploratory analyses of physiological imaging and blood biomarkers. RESULTS: Forty-five patients enrolled, and no dose toxicities were observed at a dose of cediranib 30 mg daily and cilengitide 2000 mg twice weekly. Complete response was seen in 2 participants, partial response in 2, stable disease in 13, and progression in 21; 7 participants were not evaluable. Median overall survival was 6.5 months, median progression-free survival was 1.9 months, and progression-free survival at 6 months was 4.4%. Plasma-soluble VEGFR2 decreased with treatment and placental growth factor, carbonic anhydrase IX, and SDF1&#945;, and cerebral blood flow increased. CONCLUSIONS: The combination of cediranib with cilengitide was well tolerated and associated with changes in pharmacodynamic blood and imaging biomarkers. However, the survival and response rates do not warrant further development of this combination.
Tipo de publica??o: CLINICAL TRIAL, PHASE I; JOURNAL ARTICLE; RESEARCH SUPPORT, AMERICAN RECOVERY AND REINVESTMENT ACT; RESEARCH SUPPORT, NON-U.S. GOV'T
Nome de subst?ncia:0 (Antineoplastic Agents); 0 (Biomarkers, Tumor); 0 (Protein Kinase Inhibitors); 0 (Quinazolines); 0 (Snake Venoms); 4EDF46E4GI (Cilengitide); NQU9IPY4K9 (cediranib)
para imprimir
Fotocópia
Texto completo
Autor:Shiroishi MS; Panigrahy A; Moore KR; Nelson MD; Gilles FH; Gonzalez-Gomez I; Blüml SEndere?o:Department of Radiology, Children's Hospital Los Angeles/Keck School of Medicine of USC, MS 81, 4650 Sunset Boulevard, Los Angeles, CA, 90027, USA....
Título:Combined MRI and MRS improves pre-therapeutic diagnoses of pediatric brain tumors over MRI alone.
Fonte:N 57(9):951-6, 2015 Sep.
ISSN:País de publica??o:Germany
Idioma:engResumo:INTRODUCTION: The specific goal of this study was to determine whether the inclusion of MRS had a measureable and positive impact on the accuracy of pre-surgical MR examinations of untreated pediatric brain tumors over that of MRI alone in clinical practice. METHODS: Final imaging reports of 120 pediatric patients with newly detected brain tumors who underwent combined MRI/MRS examinations were retrospectively reviewed. Final pathology was available in all cases. Group A comprised 60 subjects studied between June 2001 and January 2005, when MRS was considered exploratory and radiologists utilized only conventional MRI to arrive at a diagnosis. For group B, comprising 60 subjects studied between January 2005 and March 2008, the radiologists utilized information from both MRI and MRS. Furthermore, radiologists revisited group A (blind review, time lapse >4 years) to determine whether the additional information from MRS would have altered their interpretation. RESULTS: Sixty-three percent of patients in group A were diagnosed correctly, whereas in 10% the report was partially correct with the final tumor type mentioned (but not mentioned as most likely tumor), while in 27% of cases the reports were wrong. For group B, the diagnoses were correct in 87%, partially correct in 5%, and incorrect in 8% of the cases, which is a significant improvement (p < 0.005). Re-review of combined MRI and MRS of group A resulted 87% correct, 7% partially correct, and 7% incorrect diagnoses, which is a significant improvement over the original diagnoses (p < 0.05). CONCLUSION: Adding MRS to conventional MRI significantly improved diagnostic accuracy in preoperative pediatric patients with untreated brain tumors.
Tipo de publica??o: JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
para imprimir
Fotocópia
PubMed Central Texto completo
Autor:Rajbhandari R; McFarland BC; Patel A; Gerigk M; Gray GK; Fehling SC; Bredel M; Berbari NF; Kim H; Marks MP; Meares GP; Sinha T; Chuang J; Benveniste EN; Nozell SEEndere?o:Departments of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, Alabama, USA....
Título:Loss of tumor suppressive microRNA-31 enhances TRADD/NF-&#954;B signaling in glioblastoma.
Fonte:O 6(19):15 Jul 10.
ISSN:País de publica??o:United States
Idioma:engResumo:Glioblastomas (GBMs) are deadly tumors of the central nervous system. Most GBM exhibit homozygous deletions of the CDKN2A and CDKN2B tumor suppressors at 9p21.3, although loss of CDKN2A/B alone is insufficient to drive gliomagenesis. MIR31HG, which encodes microRNA-31 (miR-31), is a novel non-coding tumor suppressor positioned adjacent to CDKN2A/B at 9p21.3. We have determined that miR-31 expression is compromised in >72% of all GBM, and for patients, this predicts significantly shortened survival times independent of CDKN2A/B status. We show that miR-31 inhibits NF-&#954;B signaling by targeting TRADD, its upstream activator. Moreover, upon reintroduction, miR-31 significantly reduces tumor burden and lengthens survival times in animal models. As such, our work identifies loss of miR-31 as a novel non-coding tumor-driving event in GBM.
Tipo de publica??o: JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
Nome de subst?ncia:0 (MIRN31 microRNA, human); 0 (MicroRNAs); 0 (NF-kappa B); 0 (TNF Receptor-Associated Death Domain Protein)
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
Autor:Barakat LP; Li Y; Hobbie WL; Ogle SK; Hardie T; Volpe EM; Szabo MM; Reilly M; Deatrick JAEndere?o:The Children's Hospital of Philadelphia, Philadelphia, PA, USA....
Título:Health-related quality of life of adolescent and young adult survivors of childhood brain tumors.
Fonte:P 24(7):804-11, 2015 Jul.
ISSN:País de publica??o:England
Idioma:engResumo:OBJECTIVE: Our aim was to expand research on predictors of health-related quality of life (HRQOL) for adolescent and young adult survivors of childhood brain tumors who are not living independently by evaluating the mediating role of family functioning in the association of disease severity/treatment late effects with survivor self-report and caregiver-proxy report of physical and emotional HRQOL. METHODS: Mothers (N = 186) and their survivors living at home (N = 126) completed self-report and caregiver-proxy report of physical and emotional HRQOL. Mothers completed family functioning measures of general family functioning, caregiving demands, and caregiver distress. Medical file review and caregiver report were used to evaluate disease severity/treatment late effects. RESULTS: Using structural equation models, family functioning was adjusted for sociodemographic factors. Disease severity/treatment late effects had significant direct effects on self-report and caregiver-proxy report of physical and emotional HRQOL. Family functioning had a significant direct effect on caregiver-proxy report of physical and emotional HRQOL, but these findings were not confirmed for self-report HRQOL. Model-fit indices suggested good fit of the models, but the mediation effect of family functioning was not supported. CONCLUSIONS: Disease severity/treatment late effects explained self-report and caregiver-proxy report of physical and emotional HRQOL for these adolescent and young adult survivors of childhood brain tumors. Family functioning was implicated as an important factor for caregiver-proxy report only. To enhance physical and emotional HRQOL, findings underscore the importance of coordinated, multidisciplinary follow-up care for the survivors who are not living independently and their families to address treatment late effects and support family management.
Tipo de publica??o: JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
página 1 de 8703
ir para página &&&&&&&&&&&&&&&&&&&&&&&&
Base de dados :
Formulário avan?ado&&&
PalavrasDescritor de assuntoDescritor de assunto primárioLimitesAutorPalavras do títuloPalavras do resumoIdiomaPaís de publica??oNome de subst?nciaNome de pessoa como assuntoRevistaAssunto de RevistaISSNTipo de publica??oIdentificador únicoMês de entradaAno de publica??oTexto completoAtualiza??o por classeCategoria DeCSCategoria DeCS explodidaCategoria CID-10SubSetsPais de Afilia??oAfilia??oAfilia??o 2
PalavrasDescritor de assuntoDescritor de assunto primárioLimitesAutorPalavras do títuloPalavras do resumoIdiomaPaís de publica??oNome de subst?nciaNome de pessoa como assuntoRevistaAssunto de RevistaISSNTipo de publica??oIdentificador únicoMês de entradaAno de publica??oTexto completoAtualiza??o por classeCategoria DeCSCategoria DeCS explodidaCategoria CID-10SubSetsPais de Afilia??oAfilia??oAfilia??o 2
PalavrasDescritor de assuntoDescritor de assunto primárioLimitesAutorPalavras do títuloPalavras do resumoIdiomaPaís de publica??oNome de subst?nciaNome de pessoa como assuntoRevistaAssunto de RevistaISSNTipo de publica??oIdentificador únicoMês de entradaAno de publica??oTexto completoAtualiza??o por classeCategoria DeCSCategoria DeCS explodidaCategoria CID-10SubSetsPais de Afilia??oAfilia??oAfilia??o 2
Search engine:
v2.6 powered by
BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informa??o em Ciências da Saúde